ABSTRACT

Objective: To evaluate the gene expression of beta-trace protein in urine of diabetic patients, with no reduction in glomerular filtration rate, which was defined as below 60mL/min/1.73m². Methods: Type 2 diabetes mellitus patients were recruited, and a group of non-diabetic individuals served as control. Beta-trace protein gene expression was analyzed by quantitative PCR. Blood samples were collected to establish glucose levels and baseline kidney function. Accuracy was analyzed using ROC curves. Results: Ninety type 2 diabetes mellitus patients and 20 non-diabetic individuals were recruited. The area under the curve was 0.601, sensitivity of 20% and specificity of 89.47%. Among diabetic participants, 18% showed an expression above the cutoff point. Conclusion: These results of accuracy of beta-trace protein gene expression in urine of diabetic patients are promising, although they did not achieve a higher area under the curve level.

Keywords: Beta-trace protein; Prostaglandins D/biosynthesis; Diabetes mellitus, type 2; Gene expression; Biomarkers/urine

INTRODUCTION

Prostaglandin D-synthase, also known as lipocalin-type beta-trace protein (BTP), is a low-molecular-weight protein of 168 amino acids, encoded on chromosome 9. Beta-trace protein is widely present in a variety of tissues and body fluids. The molecular weight of BTP varies among its different isoforms, ranging from 23 to 29kDa. These isoforms are produced through a post-translational process of N-glycosylation, with the lower-weight isoforms being found mainly in cerebrospinal fluid, and those of higher molecular weight in the blood and urine.(1,2)

The two main serum measurements used in the diagnosis of diabetes are blood glucose and the glycated hemoglobin. As with other chronic diseases, the search for more sensitive and specific biomarkers of diabetes is important to enable earlier interventions, to minimize...
Urinary BTP gene expression was measured by isolating urinary RNA (1 μg, initially), which was then converted into first-strand cDNA with the aid of SSIII First Strand qPCR Supermix (Invitrogen, catalog number 11,752,050), according to the manufacturer’s protocol.

The expression of the specific BTP gene was assessed by quantitative real-time polymerase chain reaction (RT-qPCR). To standardize and determine the relative expression of the target gene, the reference gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was also expressed. The specific primers of the target and reference genes were designed with the help of the software Primer3 Input 0.4.0 and were checked for their specificity by the Primer-BLAST program.

For RT-qPCR, an Applied Biosystems 7500 Real Time PCR Systems (Applied Biosystems, Foster City, USA) thermal cycler was used. Each sample had a final volume of 15 μL, containing 1 x SYBR Green mix (Quantitec SYBR Green PCR kit, QIAGEN Catalog no. 204 054), 10pmol of each specific primer and 2μL of 10x-diluted cDNA. The parameters of amplification included an initial hot start at 95°C for 15 seconds, and 60°C for the primer sequence.

To verify differences in urinary beta-trace protein gene expression between groups, the mean and standard deviation were analyzed using the Student’s t test for independent samples. The median and first and third quartiles were analyzed using the Mann-Whitney test.

To verify the expression of urinary BTP gene above and below the cutoff point of 6.34, as established in the literature, the relative frequency was used. The verification of a possible association between the quantities expressed between the two groups was performed using the χ² test.

To determine the sensitivity and specificity of BTP as a predictor of diabetes, a receiver operating characteristic (ROC) curve was used. The chance of positive or negative results in diabetic patients based upon the expression of BTP was evaluated, respectively, by positive and negative likelihood ratios. The significance level was 95%. Statistical analyses were performed using Stata software version 11.0® (USA).

This study was approved by the Research Ethics Committee of the Faculdade de Medicina do ABC, under number 295.177, CAAE: 16235413.0.0000.0082.

RESULTS
A total of 110 patients were recruited for this study: 90 subjects with T2DM and 20 without diabetes serving as
the Control Group. The purpose of the control group was to validate the analysis of BTP gene expression.

The Diabetic Group had mean glycated hemoglobin of 8.38% and mean eGFR of 79.1mL/min/1.73m². Of the 90 patients, 48.8% were men and the mean age was 61.3 years. Of the 20 patients in the Control Group, 25% were men and the total mean age was 38.3 years.

Table 1 shows the mean and median expression of BTP observed. Both mean (p=0.08) and median (p=0.70) were higher for the Diabetic Group, compared to the Control Group, but no statistically significant difference between groups was encountered.

| Table 1. Beta-trace protein expression analysis between groups |
|---------------------------------------------------------------|
| Group | Mean (SD) | CV | Median (p.25;p.75) | p value* | p value † |
|-------|-----------|----|-------------------|----------|-----------|
| Control | 1.07 (5.27) | 4.93 | 2.01 (2.66; 4.15) | 0.158    | 0.080     |
| T2DM | 3.57 (5.21) | 1.46 | 2.80 (0.13; 5.42) | 0.016    | 0.080     |

* Student’s t test; † Mann-Whitney’s test. SD: standard deviation; CV: coefficient of variation; p.25-p.75: 25 and 75% percentile; T2DM: type 2 diabetes mellitus.

Figure 1 shows the diagnostic capacity of BTP as a predictor of kidney damage in people with diabetes, using the ROC curve. Near the cut-off point established by the literature (6.34), BTP as a predictor of kidney damage had a sensitivity of 20%, a specificity of 89.47%, an accuracy of 39.13%, a positive likelihood ratio of 1.90 and a negative likelihood ratio of 0.89, with an area under the curve (AUC) ROC curve of 0.610.

**DISCUSSION**

The methodology used in this study is unprecedented in the literature because instead of investigating the concentration of BTP, the variation based upon expression of the gene for BTP was measured. A possible relationship between the presence or absence of change in renal function in diabetics and the expression of BTP was verified.(5,6)

Beta-trace protein is widely found in tissues and body fluids, and increases in the concentration of BTP have been studied as a possible biomarker of reduced glomerular filtration rate. However, as with other markers, the concentration of BTP found showed great variability depending on the method of measurement used, in addition to intra-individual fluctuations. Selvin et al.,(7) evaluated the coefficient of variation among the various markers of glomerular filtration rate, such as cystatin C, beta-2 microglobulin and BTP. Of all the markers assessed, BTP, when measured in terms of mass and concentration, showed the greatest intra-individual variability.

This variability is at least partially caused by the existence of various isomers of BTP. The discrepant measurements are the result of changing relative concentrations of each isomer. Furthermore, the differences present in side-chain glycosylation, as well as differences in clearance, are dependent upon the specific fluid (blood, urine or cerebrospinal fluid) where the BTP is encountered.(8,9) Beta-trace protein in cerebrospinal fluid, with relatively low glycosylation, is excreted by the liver, where the isomers with high glycosylation rates undergo renal excretion.(8) The measurement of BTP based on gene expression, rather than on concentration, eliminates variations related to isomers.

Given this methodological advantage, the analysis of the ROC curve showed satisfactory results, taking into account that the value of 0.7 is generally considered as the lower limit for a good marker, and above 0.9 is considered to be excellent. The fact that this analysis, using gene expression, reached a value of 0.61, is promising.

Several studies have verified an increase in the concentration of BTP in diabetic patients who had already presented other signs of reduced renal function.(10,11) An increase in BTP was also verified in patients with metabolic syndrome and patients who have presented cardiovascular events, suggesting that BTP may also be used as a predictor of diabetes.(12) However, none of these studies correlated the presence of diabetes in the absence of kidney disease or other pathological conditions, such as infections or changes in cerebrospinal fluid, with increases in BTP.

**CONCLUSION**

Urinary beta-trace protein gene expression in diabetic patients had good sensitivity and specificity. These
results are promising, despite their not having achieved a higher area under the curve level.

ACKNOWLEDGMENTS
This study received funding from the State of São Paulo Research Foundation (FAPESP), number 2014/04596-8, and from the Centro de Assistência à Pesquisa em Saúde da Faculdade de Medicina do ABC.

REFERENCES
1. Orenes-Piñero E, Manzano-Fernández S, López-Cuenca Á, Marín F, Valdés M, Januzzi JL. β-Trace protein: from GFR marker to cardiovascular risk predictor. Clin J Am Soc Nephrol. 2013;8(5):873-81. Review.
2. White CA, Ghazan-Shahi S, Adams MA. β-Trace protein: a marker of GFR and other biological pathways. Am J Kidney Dis. 2015;65(1):131-46. Review.
3. Kobata M, Shimizu A, Rinno H, Hamada C, Maeda K, Fuhui M, et al. Beta-trace protein, a new marker of GFR, may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2004;18(4):237-9.
4. Bacci MR, Cavallari MR, de Rozier-Alves RM, Alves Bda C, Fonseca FL. The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes. Drug Des Devel Ther. 2015;9:3179-82. Review.
5. Filler G, Kusserow C, Lopes L, Kobrzyński M. Beta-trace protein as a marker of GFR--history, indications, and future research. Clin Biochem. 2014;47(13-14):1188-94. Review.
6. Vynczler LL, Floré KM, Delanghe SE, Delanghe JR. Urinary beta-trace protein as a new renal tubular marker. Clin Chem. 2009;55(6):1241-3.
7. Selvin E, Jurashck SJ, Eckfeldt J, Levey AS, Inker LA, Coresh J. Within-person variability in kidney measures. Am J Kidney Dis. 2013;61(5):716-22.
8. Hoffmann A, Nimtz M, Conradt HS. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 1997;7(4):499-506.
9. Tin A, Astor BC, Boerwinkle E, Hoogeveen RC, Coresh J, Kao WH. Genome-wide significant locus of beta-trace protein, a novel kidney function biomarker, identified in European and African Americans. Nephrol Dial Transplant. 2013;28(6):1497-504.
10. Uehara Y, Makino H, Seiki K, Urade Y; L-PGDS Clinical Research Group of Kidney. Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study. Nephrol Dial Transplant 2009;24(2):475-82.
11. Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76(3):358-67.
12. Cheung CL, Cheung TT, Lam KS, Cheung BM. Reduced serum beta-trace protein is associated with metabolic syndrome. Atherosclerosis. 2013;227(2):404-7.